MARKET

BMRN

BMRN

Biomarin Pharmaceutical Inc
NASDAQ
60.88
-0.24
-0.39%
Closed 17:46 03/09 EDT
OPEN
60.91
PREV CLOSE
61.12
HIGH
61.88
LOW
59.83
VOLUME
1.30M
TURNOVER
--
52 WEEK HIGH
73.18
52 WEEK LOW
50.76
MARKET CAP
11.71B
P/E (TTM)
33.73
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BMRN last week (0302-0306)?
Weekly Report · 22h ago
Assessing BioMarin Pharmaceutical (BMRN) Valuation After FDA Expands PALYNZIQ Label For Pediatric PKU
Simply Wall St · 1d ago
Absci names Ransi Somaratne chief medical officer as Andreas Busch set to retire
Reuters · 3d ago
FDA Roundup: First-Line Hernexeos, Weekly Yuviwel, Expanded Palynziq & Sogroya Indications
NASDAQ · 3d ago
Camp4 Therapeutics FY 2025 research and collaboration revenue rises 436.5% to USD 3.5 million
Reuters · 4d ago
BioMarin Pharmaceutical Is Maintained at Overweight by Barclays
Dow Jones · 5d ago
BioMarin Pharmaceutical Price Target Raised to $105.00/Share From $80.00 by Barclays
Dow Jones · 5d ago
Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $105
Benzinga · 5d ago
More
About BMRN
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

Webull offers Biomarin Pharmaceutical Inc stock information, including NASDAQ: BMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMRN stock methods without spending real money on the virtual paper trading platform.